*791 794 For patients with recent minor (NIHSS score 3) noncardioembolic ischemic stroke or high-risk TIA (ABCD2 score 4), DAPT (aspirin plus clopidogrel) should be initiated early (ideally within 12 24 hours of symptom onset and at least within 7 days of onset) and continued for 21 to 90 days, followed by SAPT, to reduce the risk of recurrent ischemic For patients with recent (< 24 hours) minor to moderate stroke (NIHSS score 5), high-risk score 6), or symptomatic intra- cranial or extracranial 30% stenosis of an artery that could account for the event, DAPT with ticagrelor plus aspirin for 30 days may be considered to reduce the risk of 30-day recur- rent stroke but may also increase the risk of serious bleeding events, including ICH.797 For patients already taking aspirin at the time of noncardioembolic ischemic stroke or TIA, the effectiveness of increasing the dose of aspirin or changing to another antiplatelet medication is not well established.410,798 800 3: Harm ASR For patients with noncardioembolic ischemic stroke or TIA, the continuous use of DAPT (aspirin plus clopidogrel) for >90 days or the use of triple antiplatelet therapy is associated with excess risk of hemorrhage.381,382,801 SR indicates systematic review. *The subgroup of patients with noncardioembolic stroke who meet clinical cri- teria for DAPT have a more specific recommendation for antiplatelet therapy as described in Recommendation 3. Synopsis Patients with stroke/TIA not attributable to other stroke causes related to specific antithrombotic rec- ommendations (eg, AF, intracranial stenosis) should receive antithrombotic therapy for the prevention of recurrent stroke. 